| Literature DB >> 19145248 |
Rajesh K Sharma1, Anna T Rogojina, K V Chalam.
Abstract
PURPOSE: Aqueous humor is intimately related to the cells of the anterior and posterior chambers, which affect its composition. Aqueous analysis provides useful information regarding physiological and pathophysiological processes in the eye. Human aqueous samples are typically less than 100 microl, limiting the usefulness of the analysis with traditional Enzyme-Linked immunoSorbant Assay (ELISA) techniques. The specific aim of this study was to investigate if whether large numbers of analytes can be identified in clinically available samples of aqueous humor and to document the detectability of certain biomarkers in the aqueous.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19145248 PMCID: PMC2622713
Source DB: PubMed Journal: Mol Vis ISSN: 1090-0535 Impact factor: 2.367
List of analytes detected in aqueous.
| 1 | Alpha-1 Antitrypsin | P01009 | mg/ml | 0.00274 | 0.000893 | 52033.62 |
| 2 | Adiponectin | Q15848 | μg/ml | 0.01054 | 0.002623 | 10.545 |
| 3 | Alpha-2 Macroglobulin | P01023 | mg/ml | 0.0006 | 0.000777 | 2.07352 |
| 4 | Alpha-Fetoprotein | P02771 | ng/ml | 0.33637 | 0.072147 | 3.911337 |
| 5 | Apolipoprotein A1 | P02647 | μg/ml | 0.72 | 0.918 | 22077.51 |
| 6 | Apolipoprotein CIII | P02656 | μg/ml | 0.023 | 0.009896 | 1733.333 |
| 7 | Apolipoprotein H | P02749 | μg/ml | 0.61937 | 0.554624 | 14076.7 |
| 8 | Beta-2 Microglobulin | P61769 | μg/ml | 0.18121 | 0.126304 | 2745.644 |
| 9 | Complement 3 | P01024 | mg/ml | 0.00161 | 0.00162 | 61454.37 |
| 10 | Cancer Antigen 125 | Q14596 | U/ml | 9.83 | 11.01929 | 11.64692 |
| 11 | Cancer Antigen 19–9 | Q9BXJ9 | U/ml | 0.11567 | 0.048019 | 2.351045 |
| 12 | CD40 | P27512 | ng/ml | 0.03338 | 0.016927 | 7.949405 |
| 13 | C Reactive Protein | P02741 | μg/ml | 0.01163 | 0.011371 | 1520.686 |
| 14 | Endothelin-1 | P05305 | pg/ml | 3.867 | 1.675357 | 2.693245 |
| 15 | EN-RAGE | P80511 | ng/ml | 0.050 | | 10.06 |
| 16 | Eotaxin | P51671 | pg/ml | 11.737 | 3.148795 | 1.431402 |
| 17 | Erythropoietin | P01588 | pg/ml | 47.02 | 54.47922 | 1.416416 |
| 18 | Ferritin | P02792 | ng/ml | 3.10333 | 0.5231 | 443.3333 |
| 19 | FGF basic | P09038 | pg/ml | 20.66 | 5.233832 | 1.054082 |
| 20 | Fibrinogen | P02671 | mg/ml | 0.00021 | 0.000133 | 4374.364 |
| 21 | G-CSF | P09919 | pg/ml | 1.26 | | 1.26 |
| 22 | Glutathione S-Transferase | P09488 | ng/ml | 0.86112 | 0.971832 | 10.65749 |
| 23 | Haptoglobin | P00739 | μg/ml | 0.5 | 0.476 | 415.6686 |
| 24 | IgA | P24071 | μg/ml | 0.97 | 0.85 | 23278.44 |
| 25 | IGF-1 | P01343 | ng/ml | 3.7295 | 4.838829 | 4.661875 |
| 26 | IgM | P20769 | mg/ml | 4.82e−5 | 2.21e−5 | 638.4106 |
| 27 | IL-1ra | P18510 | pg/ml | 5.81 | | 1.936667 |
| 28 | IL-6 | P05231 | pg/ml | 5.81 | 7.328891 | 2.381148 |
| 29 | IL-8 | P10145 | pg/ml | 4.9412 | 2.029345 | 7.038818 |
| 30 | Leptin | P41159 | ng/ml | 0.11360 | 0.178015 | 5.514887 |
| 31 | Lipoprotein (a) | P08519 | μg/ml | 0.0637 | 0.043628 | 3.445946 |
| 32 | MCP-1 | P13500 | pg/ml | 308.87 | 191.7174 | 29.69952 |
| 33 | MIP-1alpha | P10147 | pg/ml | 7.1362 | 2.41117 | 2.744712 |
| 34 | MIP-1beta | P13236 | pg/ml | 21.707 | 13.95261 | 2.863786 |
| 35 | MMP-3 | P08254 | ng/ml | 0.22912 | 0.227617 | 5.728125 |
| 36 | Myoglobin | P02144 | ng/ml | 0.924 | 0.331162 | 176 |
| 37 | PAI-1 | P05121 | ng/ml | 0.62833 | 0.483399 | 139.6296 |
| 38 | Prostatic Acid Phosphatase | P15309 | ng/ml | 0.01419 | 0.00844 | 2.075815 |
| 39 | PAPP-A | Q13219 | U/ml | 0.01645 | 0.011151 | 2.223057 |
| 40 | “Prostate Specific Antigen, Free” | P07288 | ng/ml | 0.0051 | | 1.094421 |
| 41 | RANTES | P13501 | ng/ml | 0.00233 | 0.001534 | 9.668737 |
| 42 | Serum Amyloid P | P02743 | μg/ml | 0.0096 | 0.003076 | 841.7391 |
| 43 | Stem Cell Factor | P21583 | pg/ml | 20.575 | 4.99135 | 1.85027 |
| 44 | SGOT | P17174 | μg/ml | 1.0505 | 0.466578 | 1.411962 |
| 45 | SHBG | P04278 | nmol/l | 0.1696 | 0.070577 | 652.3077 |
| 46 | Thyroxine Binding Globulin | P05543 | μg/ml | 0.29598 | 0.26957 | 4339.993 |
| 47 | Tissue Factor | P13726 | ng/ml | 0.4732 | 0.156952 | 2.813615 |
| 48 | TIMP-1 | P01033 | ng/ml | 13.742 | 11.56826 | 327.5924 |
| 49 | TNF RII | Q92956 | ng/ml | 0.07006 | 0.051629 | 107.7949 |
| 50 | Thyroid Stimulating Hormone | P01215 | U/ml | 0.0217 | 0.018148 | 3.882143 |
| 51 | VCAM-1 | P19320 | ng/ml | 2.22 | 1.408971 | 170.7692 |
| 52 | VEGF | P15692 | pg/ml | 214.987 | 91.01978 | 143.325 |
Out of 90 analytes evaluated, 52 were detectable in the aqueous samples. These included cytokines, growth factors, cell adhesion molecules immunoglobulin, components of immune system, and enzymes. VEGF is especially relevant for studying the pathobiology of various retinal disorders.
List of 10 most significant canonical pathways maps represented by detectable analytes in normal aqueous samples.
| 1 | Immune response _Histamine signaling in dendritic cells | 1.098e−7 |
| 2 | Development_Leptin signaling via JAK/STAT and MAPK cascades | 1.194e−7 |
| 3 | Immune response _Oncostatin M signaling via JAK-Stat in mouse cells | 1.335e−6 |
| 4 | Immune response _Oncostatin M signaling via JAK-Stat in human cells | 2.099e−6 |
| 5 | Immune response _Histamine H1 receptor signaling in immune response | 2.881e−6 |
| 6 | Cell adhesion_ECM remodeling | 3.911e−6 |
| 7 | Immune response _MIF-mediated glucocorticoid regulation | 1.501e−4 |
| 8 | Immune response _IL1 signaling pathway | 5.128e−4 |
| 9 | Immune response _Oncostatin M signaling via MAPK in mouse cells | 6.111e−4 |
| 10 | Immune response _Oncostatin M signaling via MAPK in human cells | 7.207e−4 |
These pathways prominently represent immune and cell adhesion pathways.
List of 10 most statistically significant canonical pathways maps represented by detectable analytes in normal aqueous samples.
| 1 | A2M, Kallikrein 3 (PSA), Alpha 1-antitrypsin, VEGF-A, PAI1 | organ development (61.4%; 4.075e−10), response to wounding (36.4%; 4.455e−10), response to external stimulus (43.2%; 4.572e−10), cell proliferation (50.0%; 5.309e−10), positive regulation of cell proliferation (31.8%; 6.986e−10) | 2.36e−31 | 61.1 | 61.1 |
| 2 | Stromelysin-1, CCL2, TIMP1, MIP-1-beta, Alpha 1-antitrypsin | response to external stimulus (47.8%; 1.468e−12), response to wounding (37.0%; 9.322e−11), wound healing (23.9%; 1.290e−10), blood coagulation (15.2%; 3.146e−07), coagulation (15.2%; 3.914e−07) | 8.46e−29 | 57.4 | 57.4 |
| 3 | VEGF-A, Endothelin-1, PAI1, Stromelysin-1, CD40(TNFRSF5) | response to stimulus (75.5%; 5.440e−14), response to stress (55.1%; 3.472e−13), protein kinase cascade (40.8%; 3.739e−13), response to external stimulus (46.9%; 7.466e−13), cell surface receptor linked signal transduction (57.1%; 1.494e−12) | 1.14e−28 | 56.8 | 56.8 |
| 4 | F3, Beta-2-glycoprotein I (APOH), VCAM1, MIP-1-beta, CCL2 | cell adhesion (53.2%; 8.293e−19), biological adhesion (53.2%; 8.293e−19), response to wounding (51.1%; 1.218e−18), localization of cell (51.1%; 5.939e−17), cell motility (51.1%; 5.939e−17) | 1.14e−28 | 56.8 | 58.1 |
| 5 | CD40(TNFRSF5), CRP, G-CSF, F3, APCS | immune system process (57.1%; 2.349e−16), immune response (44.9%; 1.384e−14), response to stimulus (73.5%; 4.961e−13), defense response (40.8%; 6.493e−12), adaptive immune response (20.4%; 1.681e−10) | 1.14e−28 | 56.8 | 56.8 |
| 6 | APOA1, PPAP, Adiponectin, APOC3, MIP-1-alpha | sterol transport (15.2%; 3.842e−08), cholesterol transport (15.2%; 3.842e−08), triacylglycerol metabolic process (12.1%; 1.119e−06), lipid transport (15.2%; 1.661e−06), response to stimulus (63.6%; 1.781e−06) | 4.46e−27 | 57.2 | 57.2 |
| 7 | CCL2, CCL5, Eotaxin, MIP-1-beta, MIP-1-alpha | cytokine and chemokine mediated signaling pathway (25.5%; 4.692e−17), locomotory behavior (38.3%; 1.594e−16), chemotaxis (31.9%; 5.793e−16), taxis (31.9%; 5.793e−16), response to external stimulus (53.2%; 1.704e−15) | 1.82e−23 | 48 | 68 |
| 8 | A2M, Endothelin-1, CCL5, IL-6, MIP-1-beta | response to stimulus (75.5%; 5.440e−14), response to external stimulus (49.0%; 7.073e−14), regulation of protein metabolic process (34.7%; 5.809e−13), defense response (42.9%; 6.006e−13), inflammatory response (34.7%; 1.171e−12) | 5.95e−21 | 43.6 | 43.6 |
| 9 | Beta-2-microglobulin, APOA1, TR2(TNFRSF14), VCAM1, GSTM1 | response to stimulus (75.0%; 1.873e−11), positive regulation of transferase activity (27.5%; 2.304e−10), positive regulation of kinase activity (25.0%; 3.531e−09), positive regulation of catalytic activity (27.5%; 2.827e−08), regulation of transferase activity (27.5%; 3.249e−08) | 4.09e−16 | 34.9 | 34.9 |
| 10 | PPAP, Thyroxine-binding globulin, Adiponectin, Epo, APOLPA | protein kinase cascade (34.3%; 2.065e−07), intracellular signaling cascade (48.6%; 2.204e−07), positive regulation of kinase activity (22.9%; 2.930e−07), positive regulation of transferase activity (22.9%; 3.458e−07), regulation of cell differentiation (25.7%; 3.570e−07) | 2.29e−14 | 33.3 | 33.3 |
Network objects represent the fraction of the number of genes from input list against total number of genes from MetaCore database for respective network. These included cell adhesion pathways, cytokine signaling pathways, and pathways for immune system processes.
List of 10 most statistically significant GeneGO processes represented by detectable analytes in normal aqueous samples.
| 1 | Response to external stimulus | 1.63e−11 |
| 2 | Response to stimulus | 2.9e−11 |
| 3 | Immune system process | 2.41e−9 |
| 4 | Response to wounding | 1.02e−8 |
| 5 | Inflammatory response | 1.04e−7 |
| 6 | Defense response | 1.36e−7 |
| 7 | Immune response | 3.86e−7 |
| 8 | Response to stress | 6.83e−7 |
| 9 | Positive regulation of cell proliferation | 7.37e−6 |
| 10 | Chemotaxis | 1.47e−5 |
Some of these processes, such as response to stress, chemotaxis, regulation of cell proliferation, wound healing, and immune system processes are relevant in ocular diseases.
List of 10 most statistically significant disease biomarkers represented by detectable analytes in normal aqueous samples.
| 1 | Vascular Diseases | 1.843e−21 |
| 2 | Arterial Occlusive Diseases | 5.575e−21 |
| 3 | Cardiovascular Diseases | 4.352e−20 |
| 4 | Arteriosclerosis | 5.866e−20 |
| 5 | Necrosis | 1.571e−18 |
| 6 | Ischemia | 9.303e−18 |
| 7 | Myocardial Ischemia | 1.746e−16 |
| 8 | Coronary Disease | 1.269e−15 |
| 9 | Infection | 1.637e−15 |
| 10 | Lung Diseases, Obstructive | 2.774e−15 |
Biomarkers for vascular diseases, ischemia, necrosis, and infection are highly relevant for ocular pathology.
Figure 1List of analytes that showed a twofold or more change in their levels in diabetic aqueous samples when compared to non-diabetic samples. The figure shows analytes that showed significant difference (2 fold or more; abscissa) between normal and the diabetic aqueous. The most prominent decrease was observed in glutathione S-transferase, and an increase in fibrinogen.
Comparison between processes in diabetic and non-diabetic aqueous humor.
| 1 | Locomotory behavior (42.6%), G-protein coupled receptor protein signaling pathway (51.1%), cell surface receptor linked signal transduction (66.0%) | 50 | 13 | 10 | 8.58e−29 | 57.35 |
| 2 | Response to external stimulus (56.2%), response to wounding (47.9%), response to stimulus (79.2%) | 50 | 14 | 1 | 1.73e−31 | 61.78 |
| 3 | Lipid transport (29.4%), sterol transport (23.5%), cholesterol transport (23.5%) | 50 | 12 | 0 | 3.44e−27 | 57.78 |
| 4 | Immune system process (54.0%), organ development (68.0%), response to stimulus (74.0%) | 50 | 13 | 0 | 8.58e−29 | 57.35 |
| 5 | Response to stimulus (75.0%), response to wounding (40.9%), response to external stimulus (47.7%) | 50 | 7 | 6 | 4.60e−14 | 31.76 |
| 1 | Response to external stimulus (50.0%), response to wounding (41.3%), cell surface receptor linked signal transduction (58.7%) | 50 | 4 | 0 | 1.33e−11 | 51.55 |
| 2 | Taxis (100.0%), chemotaxis (100.0%), locomotory behavior (100.0%) | 5 | 1 | 0 | 6.01e−04 | 40.77 |
| 1 | Response to wounding (37.2%), response to stimulus (69.8%), intracellular signaling cascade (51.2%) | 50 | 8 | 0 | 1.68e−21 | 67.49 |
| 2 | Response to external stimulus (53.8%), response to wounding (46.2%), cell surface receptor linked signal transduction (64.1%) | 44 | 5 | 0 | 8.36e−13 | 44.93 |
| 3 | Cellular di-, tri-valent inorganic cation homeostasis (100.0%), di-, tri-valent inorganic cation homeostasis (100.0%), cellular cation homeostasis (100.0%) | 27 | 2 | 0 | 3.28e−06 | 37.72 |
The table lists the top related processes, the total number of genes in the network (Size), the number of genes in the network from the input list (Target) and the number of canonical pathways used to build the network (pathways). The comparison of diabetic and non-diabetic samples shows several processes listed under unique to diabetes and unique to normal samples changed in the diabetic and non-diabetic samples.
Figure 2Distribution by canonical pathway maps in order of significance and their perturbation in diabetics. This figure shows canonical pathway maps, in order of significance and their perturbation in diabetics. Relevant to diabetes, the immune response and cell adhesion pathways were notably perturbed. Some pathways have been worked out in mouse cells and this is noted. The set of common analytes to both experiments is marked as blue/white stripes. The unique analytes are marked as colored bars (orange=diabetic, blue=normal/non-diabetic).
Figure 3Distribution by GeneGo processes in order of significance and their perturbation in diabetics. This figure shows GeneGo processes in order of significance and their perturbation in diabetics. Relevant to diabetes, the cell adhesion, inflammation and chemotaxis pathways were notably perturbed. The set of common analytes to both experiments is marked as blue/white stripes. The unique analytes are marked as colored bars (orange=diabetic, blue=normal/non-diabetic).
Figure 4Distribution by disease biomarkers in order of significance and their perturbation in diabetics. This figure shows disease biomarkers in order of significance and their perturbation in diabetics. As expected in diabetes, biomarkers for vascular disease, ischemia and infarction showed perturbation. The set of common analytes to both experiments is marked as blue/white stripes. The unique analytes are marked as colored bars (orange=diabetic, blue=normal/non-diabetic).